MOMA Therapeutics, a Casdin/Third Rock investment, is a private platform company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease. The company has raised $230M in two private financings and is expected to enter the clinic in 2024 for its lead indications in oncology.
In late 2021, Occam placed Hans Bitter, PhD as MOMA's SVP & Head, Data Science. Prior to MOMA, Bitter served as Senior Vice President Data Sciences and Chief Data Officer for Oncology at bluebird bio, where he built the company’s integrated data science function and led a team of more than 20 scientists, biostatisticians and engineers that supported both clinical and preclinical research. Prior to bluebird bio, Bitter was the global head of oncology bioinformatics at the Novartis Institutes of Biomedical Research.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.